Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03189420 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glioma Microenvironment an Exploratory Study

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 19, 2024 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 2023 to Oct 2025
    • Study completion date: Dec 2024 to Dec 2026
    v6
  2. Primary completion date: Oct 2022 to Oct 2023
    • Study completion date: Dec 2023 to Dec 2024
    v5
  3. Primary completion date: Oct 2020 to Oct 2022
    • Study completion date: Dec 2021 to Dec 2023
    v4
  4. Primary completion date: Oct 2018 to Oct 2020
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jan 2019 to Dec 2021
    • Site details revised
    v3
  5. Interventions: Tumor ressection (Procedure) to Tumor resection (Procedure)
    • Study description shortened, about 3 words
    • Study title expanded, about 3 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hospital Sirio-Libanes
14 trials monitored
See 1 trial at risk
Glioma
1,251 trials monitored
See 88 trials at risk
Glioblastoma
710 trials monitored
See 52 trials at risk
Diffuse glioms are primary brain tumors characterized by infiltrative growth and high heterogeneity, which render the disease mostly incurable. Advances in genetic analysis revealed that molecular and epigenetic alterations predict patients´s overall survival and clinical outcome. However, glioma tumorigenicity is not exclusively caused by its genetic alterations. The crosstalk between tumor cells and the surrounding microenvironment plays a crucial role in modulating glioma growth and aggressiveness. In this sense, to understand the tumor microenvironment would elucidate potential treatment alternatives. The focus will be to evaluate myeloid cells and cytokines levels.
Trial Details
NCT Number NCT03189420
Lead Sponsor Hospital Sirio-Libanes
Conditions
(from sponsor)		 Glioma of Brain
Related terms Glioblastoma, Glioma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov